BG102438A - Medicamentous form - Google Patents

Medicamentous form

Info

Publication number
BG102438A
BG102438A BG102438A BG10243898A BG102438A BG 102438 A BG102438 A BG 102438A BG 102438 A BG102438 A BG 102438A BG 10243898 A BG10243898 A BG 10243898A BG 102438 A BG102438 A BG 102438A
Authority
BG
Bulgaria
Prior art keywords
medicamentous form
medicamentous
vitromodels
formguarantees
activemedicamentous
Prior art date
Application number
BG102438A
Other languages
Bulgarian (bg)
Inventor
Ross MACRAE
Janet Smith
Original Assignee
Pfizer Research And Development Company, N.V./S.A.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Research And Development Company, N.V./S.A. filed Critical Pfizer Research And Development Company, N.V./S.A.
Publication of BG102438A publication Critical patent/BG102438A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A61K9/2846—Poly(meth)acrylates

Abstract

The invention relates to a medicamentous form with controlledrelease which is orally administered. It contains a basic activemedicamentous compound, low molecular polyethylene oxide,hydroxypropylmethylcellulose, fillers for tablet making andoptionally - one or more enterosolvent polymers. The formguarantees constant speed of releasing the medicament in in vitromodels of the gastrointestinal tract.25 claims
BG102438A 1995-11-21 1998-05-08 Medicamentous form BG102438A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9523752.5A GB9523752D0 (en) 1995-11-21 1995-11-21 Pharmaceutical formulations
PCT/EP1996/005020 WO1997018814A1 (en) 1995-11-21 1996-11-11 Pharmaceutical formulations

Publications (1)

Publication Number Publication Date
BG102438A true BG102438A (en) 1999-01-29

Family

ID=10784188

Family Applications (1)

Application Number Title Priority Date Filing Date
BG102438A BG102438A (en) 1995-11-21 1998-05-08 Medicamentous form

Country Status (29)

Country Link
EP (1) EP0862437A1 (en)
JP (1) JPH10513481A (en)
KR (1) KR19990071505A (en)
CN (1) CN1215993A (en)
AP (1) AP718A (en)
AR (1) AR004335A1 (en)
AU (1) AU709560B2 (en)
BG (1) BG102438A (en)
BR (1) BR9611626A (en)
CA (1) CA2232715A1 (en)
CO (1) CO4480020A1 (en)
CZ (1) CZ155498A3 (en)
GB (1) GB9523752D0 (en)
HR (1) HRP960554A2 (en)
HU (1) HUP9903734A3 (en)
IS (1) IS4706A (en)
MA (1) MA26410A1 (en)
MX (1) MX9804008A (en)
NO (1) NO982302L (en)
NZ (1) NZ322053A (en)
OA (1) OA10687A (en)
PE (1) PE22898A1 (en)
PL (1) PL326981A1 (en)
SK (1) SK63098A3 (en)
TN (1) TNSN96141A1 (en)
TR (1) TR199800902T2 (en)
WO (1) WO1997018814A1 (en)
YU (1) YU62096A (en)
ZA (1) ZA969722B (en)

Families Citing this family (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA200000526A1 (en) * 1997-12-16 2000-12-25 Пфайзер Продактс Инк. COMBINATION, EFFECTIVE FOR THE TREATMENT OF IMPOTENCE
EP2332522A3 (en) 1998-03-19 2011-12-07 Bristol-Myers Squibb Company Biphasic controlled release delivery system for high solubility pharmaceuticals and method
GT199900061A (en) * 1998-05-15 2000-10-14 Pfizer PHARMACEUTICAL FORMULATIONS.
EP0974343B1 (en) * 1998-07-22 2004-09-29 Pharma Pass II LLC Process for manufacturing a solid metoprolol composition
EP0987020A1 (en) * 1998-09-04 2000-03-22 Pharma Pass LLC Metoprolol composition and processes for manufacturing the same
CO5140079A1 (en) * 1998-10-14 2002-03-22 Novartis Ag PHARMACEUTICAL COMPOSITION OF SUSTAINED LIBERATION AND METHOD TO RELEASE A PHARMACEUTICALLY ACTIVE AGENT FROM SUSTAINED LIBERATION AND METHOD TO RELEASE A PHARMACEUTICALLY ACTIVE AGENT
UA67802C2 (en) * 1998-10-23 2004-07-15 Пфайзер Рісьоч Енд Дівелепмент Компані, Н.В./С.А. CONTROLLED-RELEASE FORMULATIONS FOR ORAL ADMINISTRATION CONTAINING cGMP PDE-5 INHIBITOR (VARIANTS), METHOD FOR ITS PREPARATION AND METHOD FOR TREATING ERECTILE DYSFUNCTION
US20030059467A1 (en) * 2001-09-14 2003-03-27 Pawan Seth Pharmaceutical composition comprising doxasozin
US7612112B2 (en) 2001-10-25 2009-11-03 Depomed, Inc. Methods of treatment using a gastric retained gabapentin dosage
TWI312285B (en) 2001-10-25 2009-07-21 Depomed Inc Methods of treatment using a gastric retained gabapentin dosage
US6723340B2 (en) * 2001-10-25 2004-04-20 Depomed, Inc. Optimal polymer mixtures for gastric retentive tablets
US8329217B2 (en) 2001-11-06 2012-12-11 Osmotica Kereskedelmi Es Szolgaltato Kft Dual controlled release dosage form
US7407955B2 (en) 2002-08-21 2008-08-05 Boehringer Ingelheim Pharma Gmbh & Co., Kg 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
WO2005037247A2 (en) * 2003-10-17 2005-04-28 Ranbaxy Laboratories Limited Oral matrix formulations of doxazosin
WO2005107702A2 (en) * 2004-05-11 2005-11-17 Glenmark Pharmaceuticals Limited Sustained release, mucoadhesive vaginal pharmaceutical compositions
KR100574554B1 (en) * 2004-05-28 2006-04-27 한미약품 주식회사 Sustained release composition for oral administration of niacin
DE102004054054A1 (en) 2004-11-05 2006-05-11 Boehringer Ingelheim Pharma Gmbh & Co. Kg Process for preparing chiral 8- (3-amino-piperidin-1-yl) -xanthines
KR100679111B1 (en) * 2004-11-20 2007-02-07 대우약품공업주식회사 A sustained release tablet comprising doxazosin
JP2009504796A (en) * 2005-08-22 2009-02-05 ノバルティス アクチエンゲゼルシャフト PHARMACEUTICAL COMPOSITION COMPRISING A PH-DEPENDENT PHARMACEUTICAL COMPOUND, A PH ADJUSTING AGENT AND A RETARDANT
US20090176882A1 (en) 2008-12-09 2009-07-09 Depomed, Inc. Gastric retentive gabapentin dosage forms and methods for using same
EP2359830B1 (en) 2006-04-26 2012-09-19 Supernus Pharmaceuticals, Inc. Controlled released preparations of oxcarbazepine having sigmoidal release profile
EA030606B1 (en) 2006-05-04 2018-08-31 Бёрингер Ингельхайм Интернациональ Гмбх Methods of preparing a medicament comprising polymorphs
PE20080251A1 (en) 2006-05-04 2008-04-25 Boehringer Ingelheim Int USES OF DPP IV INHIBITORS
EP1852108A1 (en) 2006-05-04 2007-11-07 Boehringer Ingelheim Pharma GmbH & Co.KG DPP IV inhibitor formulations
CN100396282C (en) * 2006-07-25 2008-06-25 山东省医药工业研究所 Slow released doxazosin mesilate capsule and its prepn process
SA07280459B1 (en) 2006-08-25 2011-07-20 بيورديو فارما إل. بي. Tamper Resistant Oral Pharmaceutical Dosage Forms Comprising an Opioid Analgesic
JP5607550B2 (en) 2008-03-11 2014-10-15 ディポメド，インコーポレイティド Gastric retentive sustained release dosage form comprising a combination of a non-opioid analgesic and an opioid analgesic
US8372432B2 (en) 2008-03-11 2013-02-12 Depomed, Inc. Gastric retentive extended-release dosage forms comprising combinations of a non-opioid analgesic and an opioid analgesic
PE20140960A1 (en) 2008-04-03 2014-08-15 Boehringer Ingelheim Int FORMULATIONS INVOLVING A DPP4 INHIBITOR
BRPI0916997A2 (en) 2008-08-06 2020-12-15 Boehringer Ingelheim International Gmbh DPP-4 INHIBITOR AND ITS USE
US20200155558A1 (en) 2018-11-20 2020-05-21 Boehringer Ingelheim International Gmbh Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral antidiabetic drug
KR101004205B1 (en) * 2008-12-17 2010-12-24 동아제약주식회사 The controlled released pharmaceutical compsitions of udenafil for sustained release property
JP5685550B2 (en) 2009-02-13 2015-03-18 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Pharmaceutical composition comprising SGLT2 inhibitor, DPP-IV inhibitor, and optionally antidiabetic agent, and use thereof
AR076341A1 (en) 2009-04-20 2011-06-01 Elcelyx Therapeutics Inc THERAPIES BASED ON BINDINGS OF CHEMIOSENSORIAL RECEPTORS. TREATMENT METHOD COMPOSITION
US9901551B2 (en) 2009-04-20 2018-02-27 Ambra Bioscience Llc Chemosensory receptor ligand-based therapies
US8828953B2 (en) 2009-04-20 2014-09-09 NaZura BioHealth, Inc. Chemosensory receptor ligand-based therapies
ES2760917T3 (en) 2009-11-27 2020-05-18 Boehringer Ingelheim Int Treatment of diabetic patients genotyped with DPP-IV inhibitors such as linagliptin
US9198861B2 (en) 2009-12-22 2015-12-01 Mallinckrodt Llc Methods of producing stabilized solid dosage pharmaceutical compositions containing morphinans
US20110150989A1 (en) * 2009-12-22 2011-06-23 Mallinkckrodt Inc. Methods of Producing Stabilized Solid Dosage Pharmaceutical Compositions Containing Morphinans
JP6034781B2 (en) 2010-05-05 2016-11-30 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Combination therapy
AU2011276254B2 (en) 2010-07-09 2016-11-03 James Trinca Green Combination immediate/delayed release delivery system for short half-life pharmaceuticals including remogliflozin
BR112013009635A2 (en) 2010-10-19 2016-07-12 Elcelyx Therapeutics Inc chemosensory receptor ligand-based therapies
US9034883B2 (en) 2010-11-15 2015-05-19 Boehringer Ingelheim International Gmbh Vasoprotective and cardioprotective antidiabetic therapy
BR112013017411B1 (en) 2011-01-07 2022-03-22 Anji Pharma (Us) Llc Use of a composition comprising metformin or a salt thereof
CN102058555A (en) * 2011-01-13 2011-05-18 北京汇诚瑞祥医药技术有限公司 Doxazosin controlled release tablet
UY33937A (en) 2011-03-07 2012-09-28 Boehringer Ingelheim Int PHARMACEUTICAL COMPOSITIONS CONTAINING DPP-4 AND / OR SGLT-2 AND METFORMIN INHIBITORS
CN102188431A (en) * 2011-05-09 2011-09-21 浙江九旭药业有限公司 Doxazosin mesylate sustained-release tablets and preparation method thereof
US8658631B1 (en) 2011-05-17 2014-02-25 Mallinckrodt Llc Combination composition comprising oxycodone and acetaminophen for rapid onset and extended duration of analgesia
US8858963B1 (en) 2011-05-17 2014-10-14 Mallinckrodt Llc Tamper resistant composition comprising hydrocodone and acetaminophen for rapid onset and extended duration of analgesia
US8741885B1 (en) 2011-05-17 2014-06-03 Mallinckrodt Llc Gastric retentive extended release pharmaceutical compositions
US20130143867A1 (en) 2011-12-02 2013-06-06 Sychroneuron Inc. Acamprosate formulations, methods of using the same, and combinations comprising the same
US9555001B2 (en) 2012-03-07 2017-01-31 Boehringer Ingelheim International Gmbh Pharmaceutical composition and uses thereof
WO2013158928A2 (en) 2012-04-18 2013-10-24 Elcelyx Therapeutics, Inc. Chemosensory receptor ligand-based therapies
EP3685839A1 (en) 2012-05-14 2020-07-29 Boehringer Ingelheim International GmbH Linagliptin for use in the treatment of albuminuria and kidney related diseases
WO2013174767A1 (en) 2012-05-24 2013-11-28 Boehringer Ingelheim International Gmbh A xanthine derivative as dpp -4 inhibitor for use in modifying food intake and regulating food preference
EP3878445A3 (en) 2013-06-05 2021-10-27 Synchroneuron Inc. Acamprosate formulations, methods of using the same, and combinations comprising the same
US9526728B2 (en) 2014-02-28 2016-12-27 Boehringer Ingelheim International Gmbh Medical use of a DPP-4 inhibitor
CN105616378A (en) * 2014-10-31 2016-06-01 康普药业股份有限公司 Fluconazole capsule and preparation method therefor
JP2019517542A (en) 2016-06-10 2019-06-24 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Combination of linagliptin and metformin

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1198386B (en) * 1982-07-06 1988-12-21 Lepetit Spa A PROTRACTED RELEASE PRODUCT CONTAINING SULOCTIDYL
US4765989A (en) * 1983-05-11 1988-08-23 Alza Corporation Osmotic device for administering certain drugs
US4837111A (en) * 1988-03-21 1989-06-06 Alza Corporation Dosage form for dispensing drug for human therapy
IL92966A (en) * 1989-01-12 1995-07-31 Pfizer Dispensing devices powered by hydrogel
DE69104045T2 (en) * 1990-07-23 1995-02-02 Alza Corp OSMOTIC DEVICE FOR DELIVERING NICOTIN TO BE ORALED.

Also Published As

Publication number Publication date
TR199800902T2 (en) 1998-09-21
MX9804008A (en) 1998-09-30
HUP9903734A2 (en) 2000-03-28
CA2232715A1 (en) 1997-05-29
ZA969722B (en) 1998-05-20
KR19990071505A (en) 1999-09-27
AU709560B2 (en) 1999-09-02
HRP960554A2 (en) 1998-02-28
JPH10513481A (en) 1998-12-22
YU62096A (en) 1999-03-04
TNSN96141A1 (en) 2005-03-15
WO1997018814A1 (en) 1997-05-29
SK63098A3 (en) 1999-05-07
HUP9903734A3 (en) 2000-04-28
NO982302D0 (en) 1998-05-20
CN1215993A (en) 1999-05-05
MA26410A1 (en) 2004-12-20
NO982302L (en) 1998-07-17
IS4706A (en) 1998-03-31
AU7572196A (en) 1997-06-11
PL326981A1 (en) 1998-11-09
PE22898A1 (en) 1998-05-07
EP0862437A1 (en) 1998-09-09
CZ155498A3 (en) 1999-03-17
GB9523752D0 (en) 1996-01-24
BR9611626A (en) 1999-06-01
AP718A (en) 1999-01-06
OA10687A (en) 2002-11-27
CO4480020A1 (en) 1997-07-09
AR004335A1 (en) 1998-11-04
NZ322053A (en) 1999-11-29
AP9600883A0 (en) 1997-01-31

Similar Documents

Publication Publication Date Title
BG102438A (en) Medicamentous form
WO1996039156A3 (en) Phosphate-binding polymers for oral administration
WO1995005184A3 (en) Phosphate-binding polymers for oral administration
DE69432559D1 (en) USE OF IRON-BINDING POLYMERS FOR THE MANUFACTURE OF A MEDICAMENT FOR ORAL ADMINISTRATION
CA2219991A1 (en) Taste masking pharmaceutical composition for oral administration
BG102313A (en) Method for the preparation of multilayer solid medicamentous forms for oral or rectal administration
WO1997038679A3 (en) Fast disintegrating oral dosage form
ATE232722T1 (en) CYCLOSPORIN BIODEGRADABLE MICRO- AND NANOSPHERES WITH CONTROLLED RELEASE
AU2002243387A1 (en) Pharmaceutical dosage form for oral administration of low molecular weight heparin
CA2197941A1 (en) A pharmaceutical tablet characterized by a showing high volume increase when coming into contact with biological fluids
WO1995022991A3 (en) Block copolymers
EP2233155A3 (en) Therapeutic polyanhydride compounds for drug delivery
CA2102630A1 (en) Pharmaceutical compositions of compacted medicaments
ATE290015T1 (en) CYCLOSPORINE DERIVATIVES, THEIR PRODUCTION AND PHARMACEUTICAL PREPARATIONS
AU3438897A (en) Stable drug form for oral administration and process for the preparation thereof
EE04606B1 (en) Use of H +, K + -ATPase Inhibitor in the manufacture of a medicament for oral administration
CA2212309A1 (en) Extended-release solid oral dosage forms of drugs having low solubility in water
CA2038744A1 (en) Pharmaceutical composition containing slightly water-soluble drug
CA2219777A1 (en) Nanoparticles for oral administration of pharmaceutical agents of low solubility
GEP20063719B (en) Prevention of Migraine Recurrence
WO2003063823A3 (en) Osmotic delivery system
BG105216A (en) Use of camptothecin derivatives , with reduced gastrointestinal toxicity
DK0667151T3 (en) Oral drug preparation containing diclofenac sodium and an organic acid
MY114084A (en) Phosphate - binding polymers for oral administration
BR9506507A (en) Galenic form of 5-nitro-imadazole derivatives pharmaceutical compositions gastro-protected microgranules of 5-nitro-imidazole derivatives and combination product